HONOLULU, HI, UNITED STATES, January 29, 2026 /EINPresswire.com/ -- PTC, a global non profit advancing digital ...
Q4 2025 Management View CEO Matthew Klein highlighted 2025 as a year of “many significant successes,” citing the initial global approvals and launch of Sephience for PKU as the main highlight. Klein ...
PTC Inc. (NASDAQ:PTC) is among the most profitable software stocks to buy now. On February 9, TheFly reported that BofA ...
With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna. | Late Thursday, PTC revealed that ...
PTC Therapeutics (NASDAQ:PTCT) reported fourth-quarter and full-year 2025 results highlighted by the initial global approvals ...
Pharmaceutical Technology on MSN
PTC pulls Translarna NDA after unfavourable FDA feedback
This verdict could spell the end for Translarna’s decades-long and tumultuous US DMD development journey.
Honorees recognized at PTC’s largest annual conference in its 48 year history Each recipient is contributing in ...
Enables faster, more collaborative product execution with a cloud-based PLM solution built to support future growth BOSTON, ...
PTC Inc. closed 30.32% short of its 52-week high of $219.69, which the company achieved on July 31st.
PTC Therapeutics announced it will withdraw the ataluren NDA for nmDMD, citing FDA concerns regarding the evidence of the agent's effectiveness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results